Survival after diagnosis with AIDS-related neurological illnesses has improved since the advent of HAART, according to an abstract presented to the eleventh European AIDS Conference (EACS). Furthermore, patients on ARV regimens containing a higher number of drugs that crossed the ‘blood-brain barrier’ and got into the central nervous system (CNS) had better survival rates.

With an emerging body of evidence showing that regular crystal meth use can cause changes to the structure and functioning of the brain, positive people have good reasons to be cautious about this drug. KIRSTY MACHON reports.